Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment
Status:
Recruiting
Trial end date:
2022-07-13
Target enrollment:
Participant gender:
Summary
This is a Phase 1, open-label, parallel-group study to evaluate the pharmacokinetics of
GSK3228836 in participants with Child-Pugh B (CP-B) cirrhosis (moderate hepatic impairment),
Child-Pugh A (CP-A) cirrhosis (mild hepatic impairment) and participants with normal hepatic
function as healthy control.